Illumina, Inc.'s acquisition of GRAIL, Inc. was disastrous and created all kinds of problems, but the company is refocusing ...

Illumina exits Nasdaq-100, reports Q3 EPS of $1.14 beating estimates, faces macroeconomic challenges, and lowers 2024 revenue ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that ...

In the rapidly evolving field of genomics, sequencing technologies play a crucial role in advancing our understanding of genetic material. Among the most prominent methods are Illumina sequencing and ...

Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader ...

PORTLAND, Maine, December 17, 2024--(BUSINESS WIRE)--Ovation.io, Inc., an organization dedicated to building best in class ...

"I'm looking for stocks that, for whatever reason, have gone down 80%, 85% from their highs," says Justin Deutsch of ...

The approval gives positive precedent for reimbursement of whole-genome sequencing (WGS) tests that could benefit companies ...

The Leukemia & Lymphoma Society estimates that by year end, 2024 will have seen 187,740 Americans diagnosed with a blood ...

Fintel reports that on December 11, 2024, Citigroup downgraded their outlook for Illumina (NasdaqGS:ILMN) from Buy to Neutral ...

Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing ...